RxDoctor Payments Data

Daniel Belew, MD

Urology · Roswell, GANPI 1306229851

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,969 of the $15,698 with a category attached, or 69.9%. It is spread thinly across 53 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2024 at $4,648 and has fallen 58.1% since, to $1,949 in 2025.

$15,698in general payments, 2019–2025

Across 345 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • EDAP Technomed Inc$2K
  • Coloplast$1K
  • Angiodynamics, Inc.$1K
  • Teleflex LLC$1K
  • Pfizer$378
  • plus $6K from 47 others

What the payments were for

  • Travel & lodging$4,58729%
  • Food & beverage$10,96970%
  • Education$1411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,698 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$626,075
Medicare patients
1,508
Services billed
12,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide79$1,159,706
XtandiEnzalutamide17$240,301
MyrbetriqMirabegron108$99,410
GemtesaVibegron37$43,878
Tamsulosin Hcl391$5,844
Estradiol48$4,225
Tolterodine Tartrate ErTolterodine Tartrate38$3,812
Alfuzosin Hcl ErAlfuzosin Hcl180$3,548
Oxybutynin Chloride ErOxybutynin Chloride141$3,318
Trimethoprim18$1,585
Finasteride118$1,517
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst97$1,368
Testosterone Cypionate35$1,095
Silodosin12$871
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen180$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$178$1,159,70679 claims
Astellas Pharma US IncXtandi, Myrbetriq$312$339,711125 claims
Sumitomo Pharma America, Inc.Gemtesa$76$43,87837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.

Other urology in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →